Pharma Journalist -

SMi Reports: There are only 3 places left, in 1 week leading industry experts within the microbiology community will be meeting in San Diego at SMi’s largest Pharmaceutical Microbiology…
Read More...

FORMA Therapeutics and HitGen announced a multiyear research collaboration and license agreement to build and screen proprietary DNA-encoded libraries (DELs). Through this collaborative…
Read More...

Aptar Pharma announced plans to collaborate on the launch of a comprehensive platform to develop digital medicines for multiple therapeutic areas and diseases. The digital medicine…
Read More...

Daiichi Sankyo Company announced the launch of Immune-mediated Inflammatory Diseases Consortium for Drug Development (hereafter, the consortium) to research and discover drugs for…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta…
Read More...

Arrowhead Pharmaceuticals announced that it has completed enrollment and dosing of all 5 planned cohorts of healthy adult volunteers in the single-ascending dose portion of its ongoing…
Read More...

Pfizer Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved XELJANZ (tofacitinib) 10 mg twice-daily (BID) for at least eight weeks, followed by…
Read More...

Five Prime Therapeutics announced it has entered into a collaboration with Roche to develop immunohistochemistry (IHC) companion diagnostic assays for use with Five Prime’s…
Read More...

Ipsen announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson’s Institute for Applied Cancer…
Read More...

Cloud Pharmaceuticals announced that they have entered into drug discovery collaboration with GlaxoSmithKline (GSK). Cloud will design novel small-molecule agents to GSK specified…
Read More...